Cost-effectiveness analysis of intensive blood-glucose control with metformin in overweight patients with Type II diabetes (UKPDS no. 51)

Diabetologia

Volumn 44, Issue 3, 2001, Pages 298-304

  Clarke, P ^a   Gray, A ^a   Adler, A ^a   Stevens, R ^a   Raikou, M ^a   Cull, C ^a   Stratton, I ^a   Holman, R ^a  

^a UNIVERSITY OF OXFORD   (United Kingdom)

Author keywords

Cost saving; Cost effectiveness analysis; Economic evaluation; Metformin; Overweight patient; Type II diabetes

Indexed keywords

METFORMIN;

ADULT; ARTICLE; BLOOD GLUCOSE MONITORING; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; COST EFFECTIVENESS ANALYSIS; FEMALE; HEALTH CARE COST; HUMAN; LIFE EXPECTANCY; MAJOR CLINICAL STUDY; MALE; NON INSULIN DEPENDENT DIABETES MELLITUS; OBESITY; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL;

ADULT; AGED; ANTIHYPERTENSIVE AGENTS; BLOOD GLUCOSE; BLOOD GLUCOSE SELF-MONITORING; BODY MASS INDEX; COST-BENEFIT ANALYSIS; COSTS AND COST ANALYSIS; CROSS-SECTIONAL STUDIES; DIABETES MELLITUS; DIABETES MELLITUS, TYPE 2; DIABETIC DIET; ENGLAND; GREAT BRITAIN; HUMANS; HYPERTENSION; HYPOGLYCEMIC AGENTS; INSULIN; METFORMIN; MIDDLE AGED; NORTHERN IRELAND; OBESITY; PATIENT EDUCATION; SCOTLAND;

EID: 0035079709     PISSN: 0012186X     EISSN: None     Source Type: Journal    
DOI: 10.1007/s001250051617     Document Type: Article

References (30)

1. Intensive blood-glucose control with sulphonylureas or insulin compared with conventional treatment and risk of complications in patients with type 2 diabetes (UKPDS 33)
2. Effect of intensive blood-glucose control with metformin on complications in overweight patients with type 2 diabetes (UKPDS 34)
3. Cost effectiveness of an intensive blood glucose control policy in patients with type 2 diabetes: Economic analysis alongside a randomised controlled trial. UKPDS 41
4. Cost-effectiveness and clinical outcomes of metformin or insulin add-on therapy in adults with type 2 diabetes
5. United Kingdom Prospective Diabetes Study (UKPDS). 13: Relative efficacy of randomly allocated diet, sulphonylurea, insulin, or metformin in patients with newly diagnosed non-insulin dependent diabetes followed for three years
6. Lifetime benefits and costs of intensive therapy as practiced in the diabetes control and complications trial
7. Cost effectiveness analysis of improved blood pressure control in hypertensive patients with type 2 diabetes: UKPDS 40
8. Model of complications of NIDDM. I. Model construction and assumptions
9. The cost-effectiveness of different management strategies for Type I diabetes: A Swiss perspective
10. Bootstrap confidence intervals: When, which, what? A practical guide for medical statisticians
11. Confidence intervals for cost-effectiveness ratios: An application of Fieller's theorem
12. The negative side of cost-effectiveness analysis
13. Costs, effects and C/E-ratios alongside a clinical trial
14. Association of glycaemia with macrovascular and microvascular complications of type 2 diabetes (UKPDS 35): Prospective observational study
15. Pharmacologic therapy for type 2 diabetes mellitus
16. First 20 months' experience with use of metformin for type 2 diabetes in a large health maintenance organization
17. Efficacy of metformin in the treatment of NID-DM. Meta-analysis
18. Causes of weight gain during insulin therapy with and without metformin in patients with Type II diabetes mellitus
19. Effects of metformin in patients with poorly controlled, insulin-treated type 2 diabetes mellitus. A randomized, double-blind, placebo-controlled trial
20. Feasibility and outcomes of insulin therapy in elderly patients with diabetes mellitus
21. Use of services by diabetes patients in managed care organizations. Development of a diabetes surveillance system
22. Economic consequences of diabetes mellitus in the U.S. in 1997
23. Handling uncertainty when performing economic evaluation of health care interventions